Raquel Gustafson Email & Phone Number

Expertly crafted healthcare solutions for big business. Save up to 22% on healthcare costs while significantly boosting health wellness for your employees.Read our case study: http://www.inhousephysicians.com/case-study-worksite-health-solution-roi/Schedule a complementary assessment:http://www.inhousephysicians.com/complementary-assessment/InHouse Physicians is a global provider of innovative onsite healthcare solutions that assist corporations in reducing healthcare claims. Using a value-based approach, our "next generation"​ worksite clinics reduce healthcare costs while improving health outcomes that matter most to patients.

Clinilabs is the only global, full-service contract research organization (CRO) focused exclusively on central nervous system (CNS) drug development. With deep expertise in CNS, we are committed to the development of medicines that treat a range of psychiatric, neurological, and substance use disorders, as well as rare and ultra-rare CNS diseases. Clinilabs partners with pharmaceutical and biotechnology companies to deliver a complete, first-in-human to Phase 3 spectrum of high-quality, timely, and cost-effective clinical drug development services, with the shared goal of speeding new CNS medicines to market. We are process-driven yet structured to be nimble, providing personalized service that meets the needs of customers and projects of all sizes. Clinilabs has conducted more than 720 CNS clinical trials since 2000 and has played a pivotal role in the approval of 20 new therapies across 11 CNS indications to help transform the lives of patients worldwide.

We bring simplicity to healthcare compliance.

Making Research Accessible:Before new medications are made available to the public, they must undergo a rigorous scientific testing process. Only the few that can continue to accumulate evidence of their safety and efficacy throughout the entire process, which starts in the laboratory and proceeds up through clinical trials with patient volunteers, are allowed to continue on the path to FDA approval.